ReviewSeminars in nephrology2012
MicroRNA circuits in transforming growth factor-β actions and diabetic nephropathy.
Review in Seminars in nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 50 citations in OpenAlex.
- MicroRNA-21 in glomerular injury.Journal of the American Society of Nephrology : JASN · 2015Trial
- Clinical Importance of miRNA in Diabetic Neuropathy: Pathophysiology, Diagnosis, and Therapeutic Potential.Current diabetes reviews · 2026Review
- miRNA in the Progression of Diabetic Kidney Disease: New Insight.International journal of molecular sciences · 2025Review
- A Promising Druggable Target for Translational Therapy of Ovarian Cancer: A Molecular Profiling of Therapeutic Innovations, Extracellular Vesicle Acquired Resistance, and Signaling Pathways.Current medicinal chemistry · 2025Review
- Understanding the Roles of Non-coding RNAs and Exosomal Non-Coding RNAs in Diabetic Nephropathy.Current molecular medicine · 2025Review
- Mechanism of Extracellular Vesicle Secretion Associated with TGF-β-Dependent Inflammatory Response in the Tumor Microenvironment.International journal of molecular sciences · 2022Review
- TGFβ acts through PDGFRβ to activate mTORC1 via the Akt/PRAS40 axis and causes glomerular mesangial cell hypertrophy and matrix protein expression.The Journal of biological chemistry · 2020Article
- Noncoding RNAs as therapeutic targets in early stage diabetic kidney disease.Kidney research and clinical practice · 2018Review
- Potential Role of Serum and Urinary Biomarkers in Diagnosis and Prognosis of Diabetic Nephropathy.Canadian journal of kidney health and disease · 2017Review
- MicroRNAs in acute kidney injury.Human genomics · 2016Review
- Anti-Inflammatory Role of MicroRNA-146a in the Pathogenesis of Diabetic Nephropathy.Journal of the American Society of Nephrology : JASN · 2016Article
- Mini-review: emerging roles of microRNAs in the pathophysiology of renal diseases.American journal of physiology. Renal physiology · 2016Review
- Epigenetics in Kidney Transplantation: Current Evidence, Predictions, and Future Research Directions.Transplantation · 2016Review
- MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.Annals of the New York Academy of Sciences · 2015Review
- Recent developments in epigenetics of acute and chronic kidney diseases.Kidney international · 2015Review
- High glucose enhances microRNA-26a to activate mTORC1 for mesangial cell hypertrophy and matrix protein expression.Cellular signalling · 2015Article
- MicroRNA-687 Induced by Hypoxia-Inducible Factor-1 Targets Phosphatase and Tensin Homolog in Renal Ischemia-Reperfusion Injury.Journal of the American Society of Nephrology : JASN · 2015Article
- Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways.The Journal of clinical investigation · 2015Article
- microRNA-21-induced dissociation of PDCD4 from rictor contributes to Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion.Experimental cell research · 2014Article
- Diabetic nephropathy--emerging epigenetic mechanisms.Nature reviews. Nephrology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Diabetes is associated with significantly increased rates of kidney disease or diabetic nephropathy (DN), a severe microvascular complication that can lead to end-stage renal disease. End-stage renal disease needs to be treated by dialysis or kidney transplantation and also is associated with cardiovascular disease and macrovascular complications. Therefore, effective renal protection is critical to reduce the rates of mortality associated with diabetes. Although key signal transduction and gene regulation mechanisms have been identified and several drugs are currently in clinical use, the rates of DN are still escalating, suggesting the imperative need to identify new biomarkers and drug targets. The recent discovery of microRNAs (miRNAs) and their cellular functions provide an opportunity to fill these critical gaps. Because miRNAs can modulate the actions of key factors involved in DN such as transforming growth factor-β, they could be novel targets for the treatment of DN. This review covers the recent studies on the roles of miRNAs and miRNA circuits in transforming growth factor-β actions and in DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.